Results 291 to 300 of about 3,106,146 (396)

Bioorthogonal Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation

Advanced Science, EarlyView.
Bioorthogonal SDPTAC harnesses US‐responsive Ce6‐TCO and Tz ligands via IEDDA click chemistry to assemble degraders in situ, generating ROS that selectively eliminate nuclear, cytosolic, and membrane proteins, thereby suppressing deep‐seated tumors in vivo.
Yuhan Bao, Yaojin Zhu, Xinhao Wei, Yuxin Fang, Jiayi Zhu, Fei Gao, Guoqiang Dong, Shipeng He, Chunquan Sheng   +8 more
wiley   +1 more source

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets [PDF]

, 2018
et al,, Li, Shunqiang, Shao, Jieya
core   +1 more source

Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review. [PDF]

Heliyon
Yang XX, Yao G, Yang Y, Han Y, Yang L, Zhang Y.   +5 more
europepmc   +1 more source

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

Advanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo, Yingge Lv, Shuyu Huang, Chang Liu, Yan Ouyang, Bei Lan, Chenghao Xuan   +6 more
wiley   +1 more source

Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors

, 2010
Sun On Chan
openalex   +2 more sources

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment. [PDF]

Sci Rep
Jeon MJ, Yu ES, Kim DS, Lee BH, Lee SR, Sung HJ, Choi CW, Park Y, Kim BS, Kang KW.   +9 more
europepmc   +1 more source

Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

Genes to Cells, 2012
M. Uyama, Mari Sato, M. Kawanami, M. Tamura   +3 more
semanticscholar   +1 more source

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

Advanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao, Xiaoli Cui, Huizhu Du, Zhuoqun Wang, Chang Liu, Linxin Zhang, Jianing Qi, Di Yang, Hui Yu, Shuang Yan, Wei Liu, Haiming Sun, Mengyang Wang   +12 more
wiley   +1 more source

The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. [PDF]

J Immunol
Ochoa TA, Rossi A, Woodle ES, Hildeman D, Allman D.   +4 more
europepmc   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, EarlyView.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source